Zemplar Related Published Studies
Well-designed clinical trials related to Zemplar (Paricalcitol)
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. [2008.08]
Calcium balance during calcitriol and paricalcitol administration in healthy humans. [2008.03]
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. [2008]
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. [2007.06]
Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. [2007.03]
Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. [2006.07]
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. [2006]
Antiproteinuric effect of oral paricalcitol in chronic kidney disease. [2005.12]
Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. [2004.07]
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. [2003.04]
Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. [2001.11]
Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. [2001.11]
A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. [2001.10]
19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. [1998.08]
Well-designed clinical trials possibly related to Zemplar (Paricalcitol)
Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. [1998.10]
Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. [1998.10]
Other research related to Zemplar (Paricalcitol)
Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. [2008.09]
Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. [2008.04]
Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. [2008.04]
The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. [2008.02]
Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis or Peritoneal Dialysis. [2007.10.03]
Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. [2007.10]
Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan. [2007]
Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism. [2007]
Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. [2007]
Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. [2006.12]
Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. [2006.10]
Paricalcitol [19-nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease. [2006.05]
Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. [2006.05]
Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease. [2006.04]
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. [2006.02]
The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar). [2006]
Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. [2006]
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. [2005.12.15]
Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. [2005.11]
Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. [2005.11]
Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. [2005.06]
Spotlight on paricalcitol in secondary hyperparathyroidism. [2005]
Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. [2005]
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. [2004.05]
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. [2003.07.31]
Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients. [2003.06]
Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up. [2003]
Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. [2001.11]
A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. [2001.10]
Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. [2000.10]
Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. [1999.03]
Other possibly related research studies
[New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics] [2005]
Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs? [2005.03]
19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. [2005.03.15]
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. [2005.04]
Are new vitamin D analogues in renal bone disease superior to calcitriol? [2005.03]
Vitamin D analogs as therapeutic agents: a clinical study update. [2004.03]
Calcimimetics versus vitamin D: what are their relative roles? [2004]
[Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient] [2003.05]
A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. [2003.06]
The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey. [2003.04]
Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. [2002.12]
Comparative review of the pharmacokinetics of vitamin D analogues. [2002.09]
Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care. [2002.09]
Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. [2002.05]
Vitamin D analogs for the treatment of secondary hyperparathyroidism. [2002]
p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. [2001.12]
Strategies to minimize bone disease in renal failure. [2001.12]
Therapeutic uses of vitamin D analogues. [2001.11]
What is the optimal regimen for vitamin D? [1999.12]
New analogs of vitamin D3. [1999.12]
Calcitriol directly sensitizes renal tubular cells to ATP-depletion- and iron-mediated attack. [1999.06]
Effect of hemodialysis on the pharmacokinetics of 19-nor-1alpha,25-dihydroxyvitamin D2. [1998.10]
Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. [1998.10]
Vitamin D analogues. [1998.10]
Vitamin D treatment in chronic kidney disease. [2005.07]
Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. [2005.07]
Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism. [2002]
Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. [2004.09]
Management of secondary hyperparathyroidism of dialysis patients. [2003.10]
Bone disease in uremic patients: advances in PTH suppression. [2002.11]
Use of vitamin D analogs in chronic renal failure. [2002.07]
Doxercalciferol treatment of secondary hyperparathyroidism. [2006.11]
Parathyromatosis and the challenge of treatment. [2006.09]
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. [2006.08]
Cardiovascular disease in chronic kidney failure: the role of VDR activators. [2006.03]
Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. [2006.06]
Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. [2006.01]
Impact of kidney bone disease and its management on survival of patients on dialysis. [2007.01]
Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both? [2006.07]
Mortality risk among hemodialysis patients receiving different vitamin D analogs. [2006.11]
Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. [2007.04]
Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. [2007]
Managing bone parameters in dialysis patients: international guideline conflicts. [2007.05]
[New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure] [2007.05]
Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs. [2007.01]
Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? [2007.03]
Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. [2006.03]
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. [2007.06]
Vascular calcification in chronic kidney failure: role of vitamin D receptor. [2007.03]
[Vitamin D treatment--which analogs and when?] [2007.05]
Relationship between vitamin D and muscle size and strength in patients on hemodialysis. [2007.11]
Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. [2008.01]
Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. [2007]
Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. [2007]
|
